OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Squadron Capital Llc Sells 16,300 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 16,300 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total value of $403,262.00. Following the completion of the transaction, the insider owned 6,881,464 shares in the company, valued at $170,247,419.36. This represents a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total value of $103,000.00.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS opened at $24.03 on Thursday. The business’s 50-day simple moving average is $21.23 and its 200-day simple moving average is $18.58. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The firm has a market cap of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. As a group, equities research analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Trending Headlines about OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Institutional Trading of OrthoPediatrics

Several institutional investors have recently bought and sold shares of KIDS. California State Teachers Retirement System grew its position in OrthoPediatrics by 397.1% in the second quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock valued at $87,000 after acquiring an additional 3,637 shares during the period. Nantahala Capital Management LLC bought a new position in shares of OrthoPediatrics during the second quarter valued at $4,636,002,000. Grandeur Peak Global Advisors LLC bought a new position in shares of OrthoPediatrics during the second quarter valued at $954,000. Bank of America Corp DE acquired a new stake in shares of OrthoPediatrics in the 2nd quarter valued at $268,000. Finally, AWM Investment Company Inc. acquired a new stake in shares of OrthoPediatrics in the 2nd quarter valued at $4,537,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on KIDS shares. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Needham & Company LLC lifted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. BTIG Research boosted their price objective on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Finally, Truist Financial set a $22.00 target price on OrthoPediatrics in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.